Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-07-07

FDA Approved: LISINOPRIL AND HYDROCHLOROTHIAZIDE — Supplemental Application (Actavis Pharma, Inc.)

View source ↗

Summary

FDA approved a supplemental application for the generic fixed-dose combination of lisinopril and hydrochlorothiazide from Actavis Pharma, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lisinopril and Hydrochlorothiazide (Lisinopril and Hydrochlorothiazide)

Snippet

SUPPL AP for LISINOPRIL AND HYDROCHLOROTHIAZIDE (LISINOPRIL AND HYDROCHLOROTHIAZIDE)